About E3 ubiquitin-protein ligase TRIM7
E3 ubiquitin-protein ligase TRIM7 (TRIM7) is a protein
from Homo sapiens identified by UniProt accession
Q9C029, 511 residues long.
MolForge cross-references it against 0 known binders and
47 disease associations.
Target properties
| Protein name | E3 ubiquitin-protein ligase TRIM7 |
| UniProt accession | Q9C029 |
| Gene | TRIM7 |
| Organism | Homo sapiens |
| Length | 511 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (47)
Diseases linked to this target (Open Targets).
- body height · score 0.32
- gut microbiome measurement · score 0.27
- glioblastoma · score 0.08
- osteosarcoma · score 0.07
- gonorrhea · score 0.07
- Sepsis · score 0.06
- neoplasm · score 0.06
- non-small cell lung carcinoma · score 0.05
- hepatocellular carcinoma · score 0.04
- BMI-adjusted waist-hip ratio · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9C029-F1 | alphafold | PREDICTED | 85.48 | — |
Amino-acid sequence (511 residues)
MAAVGPRTGP GTGAEALALA AELQGEATCS ICLELFREPV SVECGHSFCR ACIGRCWERP GAGSVGAATR APPFPLPCPQ CREPARPSQL RPNRQLAAVA TLLRRFSLPA AAPGEHGSQA AAARAAAARC GQHGEPFKLY CQDDGRAICV VCDRAREHRE HAVLPLDEAV QEAKELLESR LRVLKKELED CEVFRSTEKK ESKELLKQMA AEQEKVGAEF QALRAFLVEQ EGRLLGRLEE LSREVAQKQN ENLAQLGVEI TQLSKLSSQI QETAQKPDLD FLQEFKSTLS RCSNVPGPKP TTVSSEMKNK VWNVSLKTFV LKGMLKKFKE DLRGELEKEE KVELTLDPDT ANPRLILSLD LKGVRLGERA QDLPNHPCRF DTNTRVLASC GFSSGRHHWE VEVGSKDGWA FGVARESVRR KGLTPFTPEE GVWALQLNGG QYWAVTSPER SPLSCGHLSR VRVALDLEVG AVSFYAVEDM RHLYTFRVNF QERVFPLFSV CSTGTYLRIW P
Explore E3 ubiquitin-protein ligase TRIM7 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets